Ranibizumab (Lucentis)与afliberept (Eyelea)在农村临床实践中治疗新生血管性年龄相关性黄斑变性(nAMD)，糖尿病性黄斑水肿(DMO)和视网膜静脉闭塞(RVO)

{"title":"Ranibizumab (Lucentis)与afliberept (Eyelea)在农村临床实践中治疗新生血管性年龄相关性黄斑变性(nAMD)，糖尿病性黄斑水肿(DMO)和视网膜静脉闭塞(RVO)","authors":"N. Clements","doi":"10.37912/waggajom.0201.12","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":315668,"journal":{"name":"Wagga Wagga Journal of Medicine","volume":"57 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ranibizumab (Lucentis) vs Aflibercept (Eyelea) for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular oedema (DMO) and retinal vein occlusion (RVO) in rural clinical practice\",\"authors\":\"N. Clements\",\"doi\":\"10.37912/waggajom.0201.12\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":315668,\"journal\":{\"name\":\"Wagga Wagga Journal of Medicine\",\"volume\":\"57 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Wagga Wagga Journal of Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.37912/waggajom.0201.12\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wagga Wagga Journal of Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37912/waggajom.0201.12","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}